Invasive Aspergillosis Trial May Include Non-Licensed Comparator - FDA
Executive Summary
FDA is considering use of liposomal amphotericin B products as a comparator in first-line invasive aspergillosis trials, FDA Special Pathogens & Immunologic Drug Products Division Director Mark Goldberger, MD, indicated Jan. 10.
You may also be interested in...
Merck Cancidas Label Should Highlight Cyclosporine Data - FDA Committee
Labeling for Merck's antifungal Cancidas should include all available data on concomitant use with cyclosporine, although coadministration of the products is not recommended, FDA's Antiviral Drug Products Advisory Committee said Jan. 10.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials